NLRP3 and Parkinson disease: Informed by new insights into the involvement of mitochondrial impairment and NLRP3 inflammasome-mediated neuroinflammation in this disease, the therapeutic strategies targeting the NLRP3 inflammasome for PD treatment are discussed next, including the NLRP3 inflammatory pathway inhibitors, mitochondria-focused treatments, microRNA, and other therapeutic compounds.